Vice president of Juvenescence-backed AgeX, Aubrey de Grey, ambitiously claims that that longevity industry will “dwarf the dotcom boom.” This is a growing space due to an aging population alongside accelerating technology, burgeoning research, and the growing epidemic of chronic illnesses.
The 4 markets in longevity:
- Geroscience R&D: identifying the underlying biomedical mechanisms to aging and research methods for targeting them in order to delay or reverse aging.
- P4 Medicine: personalized, precision, preventative, participatory. This includes the application of AI for personalized care as well as identifying biomarkers of aging to empower individuals to test, measure, and improve their biological age. “Healthy Longevity means prevention rather than treatment, through the maintenance of optimal states of health via continuous monitoring of disease-associated biomarkers, and micro-adjustments in therapeutic, lifestyle and behavioral regimes to normalize those biomarkers.”
- AgeTech: broadly refers to all digital technologies that help to maintain greater functionality into older age. Its purpose being to optimize the end of life experience by providing tools, technologies, and services that improve quality of life, enhance psychological well being, mental neuroplasticity, and increase social activity in the elderly.
- While the challenges to reliable assessment, benchmarking and forecasting posed by the increasingly complex and multi-faceted industry are daunting, they are not insurmountable. It simply requires the rapid development of sophisticated, quantitative methods of analysis. And is exactly what Deep Knowledge Ventures and its Longevity-focused analytical subsidiary, Aging Analytics Agency, has set out to do over the past five years.
- More recently, these organizations have analyzing not only the biomedical aspects of Longevity but also novel Longevity-related financial frameworks, instruments and derivatives, novel InvestTech for forecasting and due-diligence within Longevity, and analysis of proactivity, strength and relevance of various nation’s government-led national Longevity development plans.
- Longevity has stronger prospects for growth than any industry in history, but its high degree of complexity poses substantial challenges and risks. Specifically, the risk of fraud, such as that experienced in gene therapy for example, the effects of which could be drastic, and set the industry’s progress back substantially. This is why we urgently need analytical frameworks that can enable assessment and optimization now, rather than later.
- Similarly, if national governments intend to progress rather than stagnate under the pressures of the oncoming Silver Tsunami, decrease the gap between their life expectancy and Healthy-Adjusted Life Expectancy, and transform the problem and deficit-model of aging into the opportunity and asset-model of Longevity, they need to embrace the development of such analytical frameworks, and utilize them to proactively prioritize Healthy Longevity as a major component of their national agendas.
Author: Margaretta Colangelo